JacekPinskiMD

Clinical Trials

• Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer Start of enrollment: 2004 Jun 01

  Completed

  Phase 2

• S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer

  Withdrawn

  Phase 2

• Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors Start of enrollment: 2006 Nov 01

  Completed

  Phase 1

• S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy Start of enrollment: 2007 Apr 01

  Completed

  Phase 2

• Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Start of enrollment: 2010 Nov 02

  Completed

  Phase 1, Phase 2

• Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer Start of enrollment: 2006 Jun 01

  Completed

  Phase 2

• Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel Start of enrollment: 2012 Jul 01

  Terminated

  Phase 2

• MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer Start of enrollment: 2016 Mar 01

  Terminated

• Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer Start of enrollment: 2018 Aug 30

  Withdrawn

• Virtual Reality in Reducing Pain and Anxiety in Cancer Participants Undergoing Painful Procedures Start of enrollment: 2022 Mar 01

  Recruiting

  Not Applicable

• Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer Start of enrollment: 2015 Sep 08

  Active, not recruiting

  Roles: Contact, Principal Investigator

• Join now to see all